Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 4,637 matching trials from the live ClinicalTrials.gov search.

Filters: Los Angeles, California Clear all

Conditions: Osteogenesis Imperfecta
Interventions: Invisalign; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 40 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Conditions: Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions: Everolimus, Tacrolimus, Mycophenolate Mofetil; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more

Conditions: Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 41
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 33 more

Conditions: GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease
Interventions: IB1001; Drug
Lead sponsor: IntraBio Inc; Industry
Eligibility: 6 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York

Conditions: Ventricular Septal Defects
Interventions: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 48
States / cities: Phoenix, Arizona • Los Angeles, California • Madera, California + 40 more

Conditions: Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
Interventions: Not listed
Lead sponsor: Marinella Temprosa; Other
Eligibility: Not listed
Enrollment: 1,976 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more

Conditions: Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions: Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Essential Tremor
Interventions: Memantine; Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cell-mediated Immune Response
Interventions: QuantiFERON Monitor Assay, Existing methodology; Device
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: pegcrisantaspase; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 43
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more

Conditions: Dental Pulp Diseases, Dental Pulp Necrosis, Nerve Root Pain Nec
Interventions: ND and AMOX modified Gutta Percha, Gutta Percha; Combination Product · Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: Venetoclax, Azacitidine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 58
States / cities: Fullerton, California • Los Angeles, California • Torrance, California + 50 more

Conditions: Insomnia, Apnea
Interventions: Insomnia treatment & PAP adherence, General sleep education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Sepulveda, California • West Los Angeles, California

Conditions: Prostatic Neoplasms
Interventions: Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 53
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Chronic Graft-versus-host-disease
Interventions: Axatilimab, Ruxolitinib, Corticosteroids; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more

Conditions: Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma
Interventions: Dordaviprone (ONC201); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
Interventions: SARS-CoV-2 and/or MIS-C Exposure; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 20 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 20
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Advance Care Planning, Advance Directives, Advanced Cancer
Interventions: Advance directive, Prepare, Facilitator; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 8,707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Irvine, California • Los Angeles, California • San Francisco, California

Conditions: Ventilator Associated Pneumonia, Nosocomial Infections in Children, Microbial Colonization
Interventions: Development and implementation of an antibiotic guideline; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Up to 3 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Vincristine Sulfate, Vinorelbine Tartrate, X-Ray Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 228
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 160 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 51
States / cities: Chandler, Arizona • Tucson, Arizona • Fullerton, California + 44 more

Conditions: HIV Infection
Interventions: Healthy Choices - Motivational Enhancement Intervention, Standard care; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 6
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Baltimore, Maryland + 2 more

Conditions: Obesity
Interventions: eloralintide and tirzepatide, Eloralintide, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 55
States / cities: Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more

Conditions: HIV Infections, Meningitis
Interventions: Quadrivalent meningococcal conjugate vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 35
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 25 more

Search by objective public record fields.

Clear Aligners for the Treatment of Dental Malocclusion in OI

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

Relapse Prevention in Stimulant Use Disorder

A Pilot Clinical Trial Of Memantine for Essential Tremor

Performance Comparison of QuantiFERON Monitor in Solid Organ Transplant Recipients

A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)

Nanodiamond-Gutta Percha Composite Biomaterials for Root Canal Therapy

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Novel Treatment of Comorbid Insomnia and Sleep Apnea in Older Veterans

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Oral ONC201 in Adult Recurrent Glioblastoma

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

UC Health Care Planning Study

Decreasing Antibiotic Use in Infants With Suspected Ventilator-associated Infection

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth